Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 125

Sort by

Sort Order Select

Journal Articles

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Sikander Ailawadhi, MD, Susanna Joan Jacobus, MSc, Rachael Sexton, MS, A. Keith Stewart, MD, Angela Dispenzieri, MD, Mohamad A. Hussein, Jeffrey Zonder, MD, John Crowley, PhD, Antje Hoering, PhD, Bart Barlogie, MD PhD, Robert Z. Orlowski, PhD, MD, S. Vincent Rajkumar, MD

Blood (2016) 128 (22): 1192.

https://doi.org/10.1182/blood.V128.22.1192.1192

Published: 2016

Journal Articles

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

Shmuel Yaccoby, Joshua Epstein, DSc, Pingping Qu, PhD, Frits van Rhee, MD PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Faith E Davies, MD, Alan Mitchell, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1808.

https://doi.org/10.1182/blood.V126.23.1808.1808

Published: 2015

Journal Articles

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

Blood (2015) 126 (23): 3181.

https://doi.org/10.1182/blood.V126.23.3181.3181

Published: 2015

Journal Articles

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Shmuel Yaccoby, PhD, Joshua Epstein, DSc, Sarah K. Johnson, PhD, Pingping Qu, PhD, Frits van Rhee, MD PhD, Yogesh Jethava, MB, MRCP, MD FRCPath, Caleb K. Stein, MS, Emily Hansen, Alan Mitchell, Maurizio Zangari, MD, Christoph Heuck, MD, Rashid Z Khan, MD, Xenofon Papanikolaou, MD, Faith E Davies, MD, Antje Hoering, PhD, John Crowley, PhD, Niels Weinhold, PhD, Bart Barlogie, MD PhD, Gareth J Morgan, MDPhD

Blood (2015) 126 (23): 1806.

https://doi.org/10.1182/blood.V126.23.1806.1806

Published: 2015

Journal Articles

Curing Multiple Myeloma (MM) with Total Therapy (TT)

Bart Barlogie, MD PhD, Alan Mitchell, Frits van Rhee, MD PhD, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Maurizio Zangari, MD, Christoph Heuck, MD, Antje Hoering, PhD, Gareth J. Morgan, MD PhD, John Crowley, PhD

Blood (2014) 124 (21): 195.

https://doi.org/10.1182/blood.V124.21.195.195

Published: 2014

Journal Articles

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Blood (2014) 124 (21): 3414.

https://doi.org/10.1182/blood.V124.21.3414.3414

Published: 2014

Journal Articles

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Caleb K Stein, MS, Pingping Qu, PhD, Joshua Epstein, DSc, Adam Rosenthal, Rachel Hunter-Merrill, Ryan Williams, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 3355.

https://doi.org/10.1182/blood.V124.21.3355.3355

Published: 2014

Journal Articles

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Rashid Z Khan, MD, Christoph Heuck, MD, Adam Rosenthal, Caleb K Stein, MS, Joshua Epstein, DSc, Shmuel Yaccoby, PhD, Xenofon Papanikolaou, MD, Yogesh Jethava, MB, MRCP, MD FRCPath, Maurizio Zangari, MD, Frits Van Rhee, Madhav V. Dhodapkar, MD, Gareth J Morgan, MD PhD, Antje Hoering, PhD, John Crowley, PhD, Bart Barlogie, MD PhD

Blood (2014) 124 (21): 2078.

https://doi.org/10.1182/blood.V124.21.2078.2078

Published: 2014

Journal Articles

Curing myeloma at last: defining criteria and providing the evidence

Bart Barlogie, Alan Mitchell, Frits van Rhee, Joshua Epstein, Gareth J. Morgan, John Crowley

Blood (2014) 124 (20): 3043–3051.

https://doi.org/10.1182/blood-2014-07-552059

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Madhav V. Dhodapkar, Rachael Sexton, Sarah Waheed, Saad Usmani, Xenofon Papanikolaou, Bijay Nair, Nathan Petty, John D. Shaughnessy, Jr, Antje Hoering, John Crowley, Robert Z. Orlowski, Bart Barlogie

Blood (2014) 123 (1): 78–85.

https://doi.org/10.1182/blood-2013-07-515239

Published: 2014

Includes: Supplemental data

Journal Articles

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Adam Rosenthal, Christoph Heuck, MD, Aziz Bakhous, M.D., Frits van Rhee, MD, PhD, Antje Hoering, PhD, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Donald Johann, MD, MS, Joshua Epstein, DSc, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1870.

https://doi.org/10.1182/blood.V122.21.1870.1870

Published: 2013

Journal Articles

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Christoph Heuck, MD, Pingping Qu, PhD, Emily Hansen, MS, Qing Zhang, PhD, Adam Rosenthal, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Shebli Atrash, MD, Purvi Patel, Antje Hoering, PhD, Joshua Epstein, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 1913.

https://doi.org/10.1182/blood.V122.21.1913.1913

Published: 2013

Journal Articles

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Saad Z Usmani, MD, FACP, Kelly Stratton, Emily Hansen, MS, Qing Zhang, PhD, Susan B. Panozzo, BS, Nathan M Petty, MS, Antje Hoering, Sarah Waheed, MD, Frits van Rhee, John Crowley, PhD, Bart Barlogie, MD

Blood (2013) 122 (21): 3191.

https://doi.org/10.1182/blood.V122.21.3191.3191

Published: 2013

Journal Articles

Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma

Christoph Heuck, MD, Pingping Qu, PhD, Frits van Rhee, MD, PhD, Sarah Waheed, MD, Saad Z Usmani, MD, FACP, Joshua Epstein, DSc, Qing Zhang, PhD, Antje Hoering, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 125.

https://doi.org/10.1182/blood.V122.21.125.125

Published: 2013

Journal Articles

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Christoph Heuck, MD, Frits van Rhee, MD, PhD, Alan Mitchell, Adam Rosenthal, Sarah Waheed, MD, Nathan M Petty, MS, Clyde Bailey, Ryan Williams, Ryan van Laar, PhD, Susan B. Panozzo, BS, Jeffrey Sawyer, PhD, John Crowley, PhD, Bart Barlogie, MD, PhD

Blood (2013) 122 (21): 126.

https://doi.org/10.1182/blood.V122.21.126.126

Published: 2013

Journal Articles

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Blood (2013) 121 (23): 4753–4757.

https://doi.org/10.1182/blood-2012-11-466961

Published: 2013

Includes: Supplemental data

Journal Articles

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

Saad Z. Usmani, Alan Mitchell, Sarah Waheed, John Crowley, Antje Hoering, Nathan Petty, Tracy Brown, Twyla Bartel, Elias Anaissie, Frits van Rhee, Bart Barlogie

Blood (2013) 121 (10): 1819–1823.

https://doi.org/10.1182/blood-2012-08-451690

Published: 2013

Includes: Supplemental data

Journal Articles

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Saad Z Usmani, MD FACP, Sarah Waheed, MD, Alan Mitchell, John Crowley, PhD, Antje Hoering, Nathan M Petty, Joshua Epstein, DSc, Christoph Heuck, MD, Shmuel Yaccoby, PhD, Donald Johann, MD, MS, Frits van Rhee, MD, PhD, Bart Barlogie, MD, Ph.D

Blood (2012) 120 (21): 2910.

https://doi.org/10.1182/blood.V120.21.2910.2910

Published: 2012

Journal Articles

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Saad Z Usmani, MD FACP, Adam Rosenthal, Rachael Sexton, Antje Hoering, Zeba N Singh, MD, Sarah Waheed, MD, Al-Ola Abdallah, MD, Jameel Muzaffar, MD, Nathan M Petty, John Crowley, PhD, Jeffrey Sawyer, PhD, Joshua Epstein, DSc, Frits van Rhee, MD, PhD, Bart Barlogie, MD, PhD

Blood (2012) 120 (21): 324.

https://doi.org/10.1182/blood.V120.21.324.324

Published: 2012

Journal Articles

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Josh Bornhorst, Adam Rosenthal, Rachael Sexton, Alan Mitchell, Linda Traylor, PhD, Antje Hoering, PhD, Frits van Rhee, MD, PhD, John Crowley, PhD, Nathan M Petty, Stephen Harding, PhD, Bart Barlogie, MD, PhD, Saad Z Usmani, MD FACP

Blood (2012) 120 (21): 3976.

https://doi.org/10.1182/blood.V120.21.3976.3976

Published: 2012

NARROW

Disease and Outcome Disparities in Multiple Myeloma (MM): Exploring the Role of Race/Ethnicity and Obesity in Cooperative Group Clinical Trials

Melphalan Affects Genes Critical for Myeloma Survival, Homing, and Response to Cytokines and Chemokines

A Prognostic 51-Gene Signature Linked to Abnormal Metaphase Cytogenetics Identifies Myeloma Patients Who Benefit from Fractionated Melphalan Dosing and Added Bortezomib, Thalidomide and Dexamethasone As Conditioning for Autologous Stem Cell Transplant

The Composition and Clinical Impact of Focal Lesions and Their Impact on the Microenvironment in Myeloma

Curing Multiple Myeloma (MM) with Total Therapy (TT)

Studies of the Proteasome Inhibitor Sensitivity Modulator Tight Junction Protein 1 Highlight a Role for Signaling through the Epidermal Growth Factor Receptor in Determining Proteasome Capacity

Modified Combat Removes Batch Effects from Myeloma Cell GEP–derived Risk Scores and Molecular Subgroup Assignment

Identifying a Gene Expression (GEP)-Based Model Predicting for Progression from AMM to Cmm Requiring Therapy in S0120 Patients Treated at Mirt

Curing myeloma at last: defining criteria and providing the evidence

Clinical, genomic, and imaging predictors of myeloma progression from asymptomatic monoclonal gammopathies (SWOG S0120)

Investigation Of The Genetic Disparities Between African Americans and Causasians Utilizing Gene Expression Profiles (GEP) Of Purified Plasma Cells (PC) and Whole Bone Marrow Biopsies (BMBx)

Comparing Gene Expression Profiling (GEP) Features Of Bone Marrow Biopsies (BMBx) Of Patients With Multiple Myeloma (MM) and Normal Donors (NL): 24 Microenvironment Specific Gene Probes Distinguish MM From NL

Final Results Of Phase II Study Of Pomalidomide (Pom) In GEP-Defined High Risk Relapsed and Refractory Multiple Myeloma (RRMM)

Five Gene Probes Carry Most Of The Discriminatory Power Of The 70-Gene Risk Model In Multiple Myeloma

Total Therapy (TT) Studies For Gene Expression Profiling (GEP)-Defined High-Risk Multiple Myeloma

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3

18-FDG PET Focal Lesion and Avidity Suppression As Early As Day-7 Post-Induction Chemotherapy Predicts for Superior Outcome in Newly Diagnosed Multiple Myeloma Patients Treated with Total Therapy 3 Trials.

Secondary Myelodysplasia-Associated Metaphase Cytogenetic Abnormalities in Newly Diagnosed Multiple Myeloma Treated On Total Therapies 2 & 3– Influence of Cumulative Dosing of Maintenance Drugs

Abnormal Hevylite Assay Ratio As a Prognostic Marker for Survival in Newly Diagnosed Multiple Myeloma Patients Treated On Total Therapy 3

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only